Skip to main content

Table 3 EQ-5D-5L and WPAI results

From: Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

  G551D/IVA patient group F508del/SOC patient group P value
EQ-5D-5L
 Index score (0–1), n; LS mean (SE) 72; 0.90 (0.02) 137; 0.81 (0.02) < 0.01
 VAS score (0–100), n; LS mean (SE) 72; 75.7 (1.8) 135; 70.0 (1.4) 0.0136
WPAI
 School, na 41 53  
 Productivity loss, n; LS mean (SE)b 27; 24.62 (6.69) 32; 34.57 (6.73) 0.3242
 Daily activities, n 70 135  
 Activity impairment, LS mean (SE)c 21.63 (2.95) 28.30 (2.19) 0.08
  1. CF Cystic fibrosis, EQ-5D-5L EuroQol 5-dimensions 5-level questionnaire, IVA Ivacaftor, LS Least squares, SE Standard error, SOC Standard of care, VAS Visual analog scale, WPAI Work Productivity Activity and Impairment Questionnaire
  2. aA total of 29 students were excluded because they were not in school over the past 2 weeks for reasons other than CF or had missing data
  3. bProductivity loss: combination of absenteeism and presenteeism representing the percentage of overall impairment due to CF
  4. cActivity impairment: percentage impact of CF on daily activities